SCHEMBL3339938

SCHEMBL3339938

CS(=O)(=O)Nc1ccc(-c2noc(-c3cn4cc(C(F)(F)F)cc(Cl)c4n3)n2)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.45
DPP7 Q9UHL4 5/20 0.45
NPC1 O15118 4/20 0.44
NFKB1 P19838 4/20 0.44
RAB9A P51151 4/20 0.44
NFKB2 Q00653 4/20 0.44
RELA Q04206 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PKM P14618 1/20 0.41
EPHX2 P34913 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340510 0.93 NPC1 (0.43) DPP4DPP7NPC1NFKB1RAB9A
SCHEMBL3339591 0.93 NPC1 (0.45) DPP4DPP7NPC1NFKB1RAB9A
SCHEMBL3340793 0.89 NPC1 (0.50) NPC1NFKB1RAB9ANFKB2RELA
SCHEMBL3340876 0.89 NPC1 (0.42) DPP4DPP7NPC1NFKB1RAB9A
SCHEMBL3341183 0.87 DPP4 (0.41) DPP4DPP7NPC1RAB9AKDM4E
SCHEMBL3340937 0.86 NPC1 (0.45) DPP4DPP7NPC1NFKB1RAB9A
SCHEMBL3340717 0.85 NPC1 (0.38) DPP4DPP7NPC1NFKB1RAB9A
SCHEMBL3340497 0.85 NPC1 (0.42) DPP4DPP7NPC1NFKB1RAB9A
SCHEMBL3341490 0.85 SMN1; SMN2 (0.43) DPP4DPP7NPC1NFKB1RAB9A
SCHEMBL3340394 0.85 SMN1; SMN2 (0.55) DPP4DPP7NPC1NFKB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 DPP4 2190/4885DPP7 1882/4885NPC1 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.